Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA Wegovy pen delivers a precisely measured dose of semaglutide — a GLP-1 receptor agonist — into the fatty tissue just beneath the skin via a short, fine needle that ejects automatically when you press the pen against your body. You don't see the needle go in, and most people feel very little. Each pre-filled pen contains four weekly doses, titrated upward by your prescriber from 0.25 mg to a maintenance dose of up to 2.4 mg (or 7.2 mg with the newer higher-dose pen), following a schedule set by your clinical team. As with any prescription-only medicine, a prescriber must assess your suitability before treatment begins, the pen itself is only part of the picture. Our full Wegovy overview covers the wider treatment journey if you'd like that context first.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Before anything else, take the pen from the fridge and let it sit at room temperature for about 30 minutes. Cold semaglutide can sting more on injection. While you wait, do a quick visual check: hold the pen up to the light and look through the inspection window. The liquid should be clear or slightly yellow and free of visible particles. If it looks cloudy, discoloured or contains floating matter, do not use it, contact your prescriber or pharmacist. That 30-second habit catches a surprising number of storage or transit issues before they become a problem.
Clean the chosen injection site with an alcohol swab and let it dry completely, wet skin can introduce minor irritation. Abdomen (at least 5 cm from the navel), outer thigh and upper arm are all licensed sites; rotate each week to avoid localised tissue changes. Alcohol swabs designed for injection-site prep are available if you need to restock. Remove the pen cap only when you're ready to inject.
The mechanism behind Wegovy injections (why semaglutide is given subcutaneously rather than orally in its injection form) is worth understanding if you're new to this route of administration.
Place the pen firmly and flat against the cleaned skin. You don't need to pinch the skin unless your prescriber has advised it for your particular site. Press the injection button fully and hold the pen in place. The device drives the needle in, delivers the dose and retracts, all in one motion. Most people describe it as a faint pressure rather than a sharp sensation.
Hold for a slow count of ten before removing the pen. This pause matters: lifting the pen too quickly can draw semaglutide back out before the full dose has dispersed into the tissue, which is exactly the kind of thing described on our page about liquid appearing after a Wegovy injection. A small dot of blood or a tiny bruise at the site is normal and not a sign of error.
For a sense of how the medicine starts working after the injection is given, the timeline for Wegovy's effects explains what to expect in the hours and days that follow, including why appetite changes are often gradual rather than immediate.
Once the pen has clicked and locked, it's spent. The needle is automatically covered, you won't re-expose it. Place the used pen in a sharps container rather than the household bin; local pharmacies accept these for safe disposal. Do not attempt to remove or recap the needle.
Common side effects in the days after injection are mostly gastrointestinal: nausea, loose stools, constipation, reflux or belching. These tend to be most noticeable early in treatment or after a dose step-up, and usually settle within a week or two as your system adjusts. Eating smaller, lower-fat meals and staying hydrated helps considerably. The NHS semaglutide patient information at nhs.uk/medicines/semaglutide lists the full side-effect profile clearly.
Seek medical help promptly for severe, persistent stomach pain that radiates toward the back, this can indicate pancreatitis, a known but infrequent risk the MHRA flagged in a 2026 Drug Safety Update for GLP-1 medicines. The MHRA Yellow Card service is the right place to report any suspected side effect, however minor it seems.
Treatment opens at 0.25 mg, a dose whose job is purely to let your body adjust, not to produce weight loss. Your prescriber then moves you up through 0.5 mg, 1.0 mg and 1.7 mg toward the 2.4 mg maintenance dose, spending roughly four weeks at each level. People who tolerate each step well tend to experience fewer side effects at the next. The 7.2 mg pen, approved by the MHRA in April 2026, follows the same staged philosophy with its own titration path.
How quickly semaglutide begins to affect appetite varies between individuals. This page on semaglutide's working timeline covers the pharmacokinetics in plain terms. And if you're comparing this injection format with Ozempic (which is also semaglutide but licensed for type 2 diabetes rather than weight management) the comparison page sets out the licensing distinction clearly.
Cost is a reasonable question once you understand the treatment itself. The Wegovy cost page covers what private treatment typically involves and why the price varies by dose and provider. If you're considering whether Wegovy is the right route for you, our weight-loss treatment overview sets out the options available, and you can check your eligibility with our prescribers at any point, free, with no commitment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.